MedTrace Logo

PMS Study Ultravist-IMAGE, IoproMide (UltrAvist) to Gain Further Information on Tolerability and Safety in X-ray Examination

NCT00876083 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 44920

Last updated 2011-02-28

No results posted yet for this study

Summary

The purpose of this study is to obtain data on the safety and efficacy of Ultravist application in usual daily use.The radiologist will administer the contrast medium to the patient as he/she would have done without the study. No other examinations will be performed than would have been done routinely.

Conditions

  • Diagnostic Imaging

Interventions

DRUG

Ultravist (Iopromide, BAY86-4877)

Patients with indication for an X-ray examination and for whom the radiologist has decided to use the contrast medium Ultravist.

Sponsors & Collaborators

Principal Investigators

  • Bayer Study Director · Bayer

Eligibility

Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2008-03-31
Primary Completion
2009-09-30
Completion
2009-09-30

Countries

  • Bosnia and Herzegovina
  • China
  • Germany
  • Hungary
  • Indonesia
  • Iran
  • Italy
  • Malaysia
  • Moldova
  • Pakistan
  • Philippines
  • Poland
  • Romania
  • Russia
  • Saudi Arabia
  • Singapore
  • South Korea
  • Taiwan
  • Thailand
  • Ukraine
  • Vietnam

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00876083 on ClinicalTrials.gov